NATCAPSUQ

Natural Capsules Limited

· Pharma & Health
₹ CrorePeersNECLIFEAAREYDRUGSBALPHARMAALPAKREBSBIOMEDICAMEQMEDICOVINEETLAB
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity0.24-7.27-7.27
Return on Assets0.15-5.81-5.81
Return on Capital Employed2.63-6.42-6.42
Return on Invested Capital0.93-4.74-4.63
Margins
EBITDA Margin10.35-0.83-0.40
Operating Margin4.96-9.99-9.99
Incremental Operating Margin-150.58
Pretax Margin1.65-14.91-14.52
Net Income Margin0.36-13.17-13.02
Net Income to Common Margin-9.12
FCF Margin-10.57-0.33-0.33
Additional
Effective Tax Rate77.8811.6610.34
Sustainable Growth Rate0.24-7.27-7.27
Incremental Operating Margin %-150.5819.42
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.